CUAMC
China Universal Asset Management Company Portfolio holdings
AUM
$1.06B
1-Year Return
31.81%
This Quarter Return
+16%
1 Year Return
+31.81%
3 Year Return
+205.04%
5 Year Return
–
10 Year Return
–
AUM
$324M
AUM Growth
+$28.5M
(+9.6%)
Cap. Flow
-$70.4K
Cap. Flow
% of AUM
-0.02%
Top 10 Holdings %
Top 10 Hldgs %
32.96%
Holding
465
New
18
Increased
159
Reduced
244
Closed
13
Top Buys
| 1 |
Vanguard World Funds Extended Duration ETF
EDV
|
$3.28M |
| 2 |
Tesla
TSLA
|
$2.24M |
| 3 |
Apple
AAPL
|
$2.14M |
| 4 |
Meta Platforms (Facebook)
META
|
$2.1M |
| 5 |
Vaxcyte
PCVX
|
$2M |
Top Sells
| 1 |
iQIYI
IQ
|
$4.85M |
| 2 |
Amazon
AMZN
|
$4.7M |
| 3 |
Airbnb
ABNB
|
$3.2M |
| 4 |
Analog Devices
ADI
|
$2.94M |
| 5 |
KE Holdings
BEKE
|
$1.93M |
Sector Composition
| 1 | Technology | 41.8% |
| 2 | Consumer Discretionary | 21.38% |
| 3 | Healthcare | 19.26% |
| 4 | Communication Services | 6.74% |
| 5 | Financials | 4.12% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
251
Edwards Lifesciences
EW
$47.5B
| $24.1K | 0.01% |
256
| – | – |
|
252
Pacira BioSciences
PCRX
$1.19B
| $24.1K | 0.01% |
602
-21
| -3% | -$841 |
|
|
BLU
253
DELISTED
BELLUS Health Inc.
BLU
| $24.1K | 0.01% |
1,634
-71
| -4% | -$1.05K |
|
254
Zscaler
ZS
$42.7B
| $24K | 0.01% |
164
+120
| +273% | +$17.6K |
|
255
Summit Therapeutics
SMMT
$19.3B
| $23K | 0.01% |
9,145
-308
| -3% | -$773 |
|
256
Zai Lab
ZLAB
$3.42B
| $22.6K | 0.01% |
814
-131
| -14% | -$3.63K |
|
257
Zentalis Pharmaceuticals
ZNTL
$126M
| $22K | 0.01% |
779
+6
| +0.8% | +$169 |
|
258
Genmab
GMAB
$16.9B
| $21.9K | 0.01% |
577
-55
| -9% | -$2.09K |
|
259
Ironwood Pharmaceuticals
IRWD
$188M
| $21.7K | 0.01% |
2,036
-53
| -3% | -$564 |
|
|
SWTX
260
DELISTED
SpringWorks Therapeutics
SWTX
| $21.5K | 0.01% |
820
-27
| -3% | -$708 |
|
261
Maravai LifeSciences
MRVI
$363M
| $21.5K | 0.01% |
1,729
-57
| -3% | -$708 |
|
262
Supernus Pharmaceuticals
SUPN
$2.58B
| $21.5K | 0.01% |
714
-19
| -3% | -$571 |
|
263
Geron
GERN
$893M
| $21.4K | 0.01% |
6,669
+747
| +13% | +$2.4K |
|
264
Rocket Pharmaceuticals
RCKT
$354M
| $20.9K | 0.01% |
1,054
-21
| -2% | -$417 |
|
265
Protagonist Therapeutics
PTGX
$3.77B
| $20.7K | 0.01% |
750
+83
| +12% | +$2.29K |
|
266
Iovance Biotherapeutics
IOVA
$901M
| $20.7K | 0.01% |
2,942
-96
| -3% | -$676 |
|
267
Agios Pharmaceuticals
AGIO
$2.09B
| $20.6K | 0.01% |
729
-20
| -3% | -$566 |
|
268
Relay Therapeutics
RLAY
$710M
| $20K | 0.01% |
1,594
-50
| -3% | -$628 |
|
269
Arcellx
ACLX
$4.03B
| $19.9K | 0.01% |
629
+35
| +6% | +$1.11K |
|
270
Xencor
XNCR
$610M
| $19.8K | 0.01% |
792
-22
| -3% | -$549 |
|
271
SiriusXM
SIRI
$8.1B
| $19.8K | 0.01% |
437
+319
| +270% | +$14.4K |
|
272
Amylyx Pharmaceuticals
AMLX
$910M
| $19K | 0.01% |
880
-17
| -2% | -$367 |
|
273
IQVIA
IQV
$31.9B
| $18.9K | 0.01% |
84
| – | – |
|
274
Syndax Pharmaceuticals
SNDX
$1.47B
| $18.9K | 0.01% |
902
-26
| -3% | -$544 |
|
275
Charles River Laboratories
CRL
$8.07B
| $18.7K | 0.01% |
89
| – | – |
|